RENGER JOHN (Chief Scientific Officer) sold 25.3% of their position (2.16K shares) of CEREVEL THERAPEUTICS HOLDINGS, INC. on the open market
Open‑market sale worth $89.8K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/8/2024ACC: 0000950170-24-012962
Officer· Chief Scientific Officer
Since Oct 2020
-2.16K
Net shares
Net seller
$89.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
5.02K acquired · 7.18K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5.02K
Price / share
—
Trade value
—
% of position
143.0%
2/6/2024
3.51K→8.53K
Common Stock
Direct
Shares
−2.16K
Price / share
$41.54
Trade value
$89.78K
% of position
25.3%
2/7/2024
8.53K→6.37K
Total
Net shares
+2.86K
Net value
-$89.78K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/6/2024 | M · Option Exercise | +5.02K | — | — | 143.0% | 3.51K | 8.53K |
| Common Stock Direct | 2/7/2024 | S · Sale | −2.16K | $41.54 | $89.78K | 25.3% | 8.53K | 6.37K |
| Total | +2.86K | -$89.78K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
5.02K shares
Shares
−5.02K
Strike price
Held after
15.06K
Exercisable
—
2/6/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock5.02K shares | 2/6/2024 | M · Option Exercise | −5.02K | — | 15.06K |